Apellis and Sobi’s Empaveli clinches FDA approval for rare kidney diseases

Apellis Pharmaceuticals and Sobi’s Empaveli secured an FDA label expansion for two kidney diseases on Monday, opening up a market of around 5,000 patients in the US. The FDA approved the ...